Literature DB >> 4067206

Immunoreactive prolactin like material in the urine of women.

V Ghuysen, J R Van Cauwenberge, A Reuter, Y Vrindts-Gevaert, P Franchimont.   

Abstract

Immunoreactive prolactin-like material (Ir Prl) was detected in urines of eugonadal women during the luteal phase and in urines of pregnant and lactating women. The levels of Ir Prl urinary excretion per 24 h and of elimination per 100 ml of glomerular filtrate were highest in lactating women as compared to pregnant women; levels in pregnant women were elevated as compared to eugonadal subjects. Iv injection of thyrotropin releasing hormone (TRH, 200 micrograms) caused increased levels of urinary Ir Prl. The physiochemical characteristics of urinary Ir Prl of lactating women were investigated by filtrating urine samples on Ultragel Aca 54 in presence or absence of Trasylol. Urines, supplemented with Trasylol and analyzed either immediately or after storage at room temperature for 24 h, contained in addition to the 23,000 Mr monomeric form (25.2 +/- 7.4%), two fractions of high (greater than or equal to 70,000) or low (less than 23,000) molecular weight, respectively. The latter material largely predominated (73.5 +/- 7.3%). Urines kept at room temperature for 24 h without Trasylol showed variable but significant decreases in the monomer form with a parallel increase in high MW and fragmented forms. The extent of degradation of the monomer was directly proportional to the proteolytic activity of the urines as estimated by the Azocoll breakdown test. Contrary to what was observed with the urinary endogenous monomeric Prl, human pituitary Prl remained unaltered upon incubation in Trasylol-free urines up to 45 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4067206     DOI: 10.1007/BF03348512

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  10 in total

1.  Homologous radioimmunoassay for human prolactin.

Authors:  A M Reuter; F Kennes; Y Gevaert; P Franchimont
Journal:  Int J Nucl Med Biol       Date:  1976-01

2.  Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of "Big" prolactin in a radioreceptor assay and evidence for its secretion.

Authors:  P E Garnier; M L Aubert; S L Kaplan; M M Grumbach
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

3.  Radioimmunoassay of prolactin in the urine of mouse and man.

Authors:  Y N Sinha; F W Selby; W P VanderLaan
Journal:  J Clin Endocrinol Metab       Date:  1973-05       Impact factor: 5.958

4.  Direct radioimmunoassay of human prolactin in semen, serum and urine.

Authors:  G Goldhaber; J Shani
Journal:  J Endocrinol       Date:  1977-03       Impact factor: 4.286

5.  Size heterogeneity of human prolactin in plasma and pituitary extracts.

Authors:  H K Suh; A G Frantz
Journal:  J Clin Endocrinol Metab       Date:  1974-11       Impact factor: 5.958

6.  Studies on prolactin in human serum, urine and milk.

Authors:  R R Gala; A Singhakowinta; M J Brennan
Journal:  Horm Res       Date:  1975

7.  Demonstration of biological activity of prolactin molecular weight variants in human sera.

Authors:  M D Whitaker; G G Klee; P C Kao; R V Randall; D W Heser
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

8.  Prolactin of apparent large molecular size: the major immunoactive prolactin component in plasma of a patient with a pituitary tumor.

Authors:  A D Rogol; S W Rosen
Journal:  J Clin Endocrinol Metab       Date:  1974-04       Impact factor: 5.958

9.  Metabolic clearance and production rates of prolactin in man.

Authors:  D S Cooper; E C Ridgway; B Kliman; R N Kjellberg; F Maloof
Journal:  J Clin Invest       Date:  1979-12       Impact factor: 14.808

10.  Heterogeneity of human growth hormone and prolactin secreted in vitro: Immunoassay and radioreceptor assay correlations.

Authors:  J H Guyda
Journal:  J Clin Endocrinol Metab       Date:  1975-11       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.